Current treatment of acute promyelocytic leukemia.
Lo Coco
Francesco
F
Ammatuna
Emanuele
E
Sanz
Miguel A
MA
D000818:Animals; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D000077237:Arsenic Trioxide; D001152:Arsenicals / Q000008:administration & dosage / Q000494:pharmacology; D014408:Biomarkers, Tumor / Q000097:blood / Q000235:genetics; D002986:Clinical Trials as Topic; D003199:Computer Systems; D019468:Disease Management; D016903:Drug Monitoring; D006412:Hematopoietic Stem Cells / Q000187:drug effects; D006801:Humans; D015473:Leukemia, Promyelocytic, Acute / Q000097:blood / Q000188:drug therapy* / Q000235:genetics; D007958:Leukocyte Count; D051379:Mice; D015337:Multicenter Studies as Topic; D015514:Oncogene Proteins, Fusion / Q000097:blood / Q000235:genetics / Q000502:physiology; D010087:Oxides / Q000008:administration & dosage / Q000494:pharmacology; D016133:Polymerase Chain Reaction / Q000379:methods; D011237:Predictive Value of Tests; D012008:Recurrence; D012680:Sensitivity and Specificity; D014162:Transfection; D014212:Tretinoin / Q000008:administration & dosage / Q000494:pharmacology
D001152:Arsenicals; D014408:Biomarkers, Tumor; D015514:Oncogene Proteins, Fusion; D010087:Oxides; C093476:promyelocytic leukemia-retinoic acid receptor alpha fusion oncoprotein; D014212:Tretinoin; D000077237:Arsenic Trioxide